BioCentury
ARTICLE | Company News

Aduro reducing headcount by 37%, focusing on STING

February 1, 2019 7:48 PM UTC

Aduro Biotech Inc. (NASDAQ:ADRO) said it will reduce headcount by 37% to focus on discovery and development of compounds against STING, via its deals with Novartis AG (NYSE:NVS; SIX:NOVN) and Eli Lilly and Co. (NYSE:LLY), and against TNFSF13.

Aduro said it will seek to partner several deprioritized programs, including its personalized live-attenuated, double-deleted Listeria monocytogenes (pLADD) immunotherapy, anti-CTLA-4 mAb ADU-1604 and anti-SIRPA antibody ADU-1805...